[go: up one dir, main page]

M. Alauddin et al., 2015 - Google Patents

Current and future trends in early detection of pancreatic cancer: molecular targets and PET probes

M. Alauddin et al., 2015

Document ID
12197546427895747350
Author
M. Alauddin M
De Palatis L
Publication year
Publication venue
Current Medicinal Chemistry

External Links

Snippet

Early detection of pancreatic cancer has been a long-standing challenge in determining prognosis and management of the deadly disease. Although the incidence of pancreatic cancer is low (2% of all malignancies), it is the fourth leading cause of deaths attributable to …
Continue reading at www.benthamdirect.com (other versions)

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • G01N33/574Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57419Specifically defined cancers of colon
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • G01N33/574Immunoassay; Biospecific binding assay for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/0493Steroids, e.g. cholesterol, testosterone
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01RMEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00Arrangements or instruments for measuring magnetic variables
    • G01R33/20Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2223/00Investigating materials by wave or particle radiation

Similar Documents

Publication Publication Date Title
Ming et al. Progress and future trends in PET/CT and PET/MRI molecular imaging approaches for breast cancer
Schwenck et al. Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT
Mankoff et al. Tumor-specific positron emission tomography imaging in patients:[18F] fluorodeoxyglucose and beyond
Ulaner PET/CT for patients with breast cancer: where is the clinical impact?
Komar et al. Decreased blood flow with increased metabolic activity: a novel sign of pancreatic tumor aggressiveness
M. Alauddin et al. Current and future trends in early detection of pancreatic cancer: molecular targets and PET probes
Rohren et al. Clinical applications of PET in oncology
Quon et al. FDG-PET and beyond: molecular breast cancer imaging
Yap et al. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography
Yamamoto et al. Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer
Margolis et al. Molecular imaging techniques in body imaging
Michalski et al. Molecular imaging in cancer treatment
Specht et al. Advances in molecular imaging for breast cancer detection and characterization
McKnight et al. 89Zr‐ImmunoPET companion diagnostics and their impact in clinical drug development
Kim et al. Usefulness of MRI-assisted metabolic volumetric parameters provided by simultaneous 18F-fluorocholine PET/MRI for primary prostate cancer characterization
De Bree et al. Advances in imaging in the work-up of head and neck cancer patients
Vaidya et al. The continuing evolution of molecular functional imaging in clinical oncology: the road to precision medicine and radiogenomics (Part I)
Kurihara et al. Molecular imaging using PET for breast cancer
Wu et al. Near-infrared fluorescence and nuclear imaging and targeting of prostate cancer
Cintolo et al. Diagnostic and prognostic application of positron emission tomography in breast imaging: emerging uses and the role of PET in monitoring treatment response
Oehr et al. Imaging of prostate cancer
Rioja et al. Role of positron emission tomography in urological oncology
Mankoff Molecular imaging as a tool for translating breast cancer science
Lawrentschuk et al. Functional imaging of renal cell carcinoma
Mahajan et al. Clinical applications of PET/CT in oncology